Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis

Qiao, Weiqiang; Liu, Heyang; Guo, Wanying; Li, Peng; Deng, Miao

doi:10.1016/j.ejso.2018.12.019

Cited by 22 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The best prognosis had patients with stromal Sdc1 positivity and cytoplasmic negativity, and the worst prognosis patients with opposite findingscytoplasmic positivity and stromal negativity, so they connected cytoplasmic Sdc1 expression with aggressive, and stromal with a more favourable outcome (49). Similar correlations between Sdc1 over-expression with main prognostic factors and poor overall survival in breast cancer were obtained by other authors (50,51).…”

Section: Some More Recent Morphological and Clinical-prognostic Studies About Sdc1 In Breast Cancersupporting

confidence: 68%

Value of immunohistochemical determination of syndecan-1 in breast cancer

Miše

2021

lib oncol

View full text Add to dashboard Cite

Syndecan-1 (Sdc1) is a transmembrane heparan-sulfate proteoglycan, an extracellular matrix receptor and a cell-matrix adhesion organiser, included in adhesion of all cell's contact surfaces. It integrates different cellular signals and signals between growth factors, and modulates cell proliferation, carcinogenesis, migration and angiogenesis. Cellular motion and invasion first require loss of the Sdc1. Sdc1 expression is lost shortly before the cell changes shape or location, which decrease adhesiveness but enhance cellular mobility and their invasive potential. Releasing of Sdc1 from the cell surface (shedding) enables tumor growth and metastasizing. Such change of the Sdc1 expression is of crucial value for transition of invasive breast carcinoma to metastatic phenotype, and it is a part of epithelial-to-mesenchymal transition (EMT). Molecules included in EMT are potential targets for anticancer pharmacotherapy and control of tumor metastasizing. Maybe proteolytic conversion from insoluble (membrane bound coreceptor) to soluble Sdc1 is trigger for turning of proliferative phase of breast cancer to invasive one, which can also be of potential diagnostic-therapeutic benefit. Stromal Sdc1 expression means not merely the simple fixation of the released Sdc1 from the epithelial cells to the stromal, but also autochthonous Sdc1 synthesis in reactive stromal fibroblasts. By interacting with heparin-binding growth factors, Sdc1 accumulates in the stroma and can contribute to proliferation of invasive tumor stroma and neoangiogenesis. In more than 70% of breast carcinomas Sdc1 is induced in stromal fibroblasts, with the significant difference in its expression between stroma of malignant and non-malignant breast tissue. Although part of breast cancers loses Sdc1, in most of them it is expressed or over-expressed, and its expression is associated with a poorer response of this cancer to chemotherapy. Studies about prognostic significance of Sdc1 in breast cancer have shown unequal results, which refers to the need for new researches on this subject.

show abstract

Section: Some More Recent Morphological and Clinical-prognostic Studies About Sdc1 In Breast Cancersupporting

confidence: 68%

Value of immunohistochemical determination of syndecan-1 in breast cancer

Miše

2021

lib oncol

View full text Add to dashboard Cite

show abstract

“…Notably, high levels of Sdc-1 in breast cancer cells correlated with higher incidence of brain metastasis (Sayyad et al, 2019). Sdc-1 is also more abundant in the ER-negative tumors, suggesting that its expression marks this more aggressive breast cancer phenotype (Barbareschi et al, 2003;Baba et al, 2006;Qiao et al, 2019). This has been corroborated by reports showing that Sdc-1 expression is directly repressed by ER (Fleurot et al, 2019).…”

Section: Syndecan-1 (Sdc-1)supporting

confidence: 56%

Proteoglycans as Mediators of Cancer Tissue Mechanics

Barkovskaya

Buffone

Žídek

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Proteoglycans are a diverse group of molecules which are characterized by a central protein backbone that is decorated with a variety of linear sulfated glycosaminoglycan side chains. Proteoglycans contribute significantly to the biochemical and mechanical properties of the interstitial extracellular matrix where they modulate cellular behavior by engaging transmembrane receptors. Proteoglycans also comprise a major component of the cellular glycocalyx to influence transmembrane receptor structure/function and mechanosignaling. Through their ability to initiate biochemical and mechanosignaling in cells, proteoglycans elicit profound effects on proliferation, adhesion and migration. Pathologies including cancer and cardiovascular disease are characterized by perturbed expression of proteoglycans where they compromise cell and tissue behavior by stiffening the extracellular matrix and increasing the bulkiness of the glycocalyx. Increasing evidence indicates that a bulky glycocalyx and proteoglycan-enriched extracellular matrix promote malignant transformation, increase cancer aggression and alter anti-tumor therapy response. In this review, we focus on the contribution of proteoglycans to mechanobiology in the context of normal and transformed tissues. We discuss the significance of proteoglycans for therapy response, and the current experimental strategies that target proteoglycans to sensitize cancer cells to treatment.

show abstract

“…It has been reported that TGF-β1 induced EMT via repression of BMP5 in breast cancer [ 47 ]. SDC1, another EMT marker identified in this study, can be used to assess the tumor prognosis [ 48 ], including breast cancer, wherein increased expression levels of SDC1 are associated with the worst prognosis [ 49 ]. This observation is confirmed by findings obtained in our study.…”

Section: Discussionmentioning

confidence: 99%

Cancer-Associated Stemness and Epithelial-to-Mesenchymal Transition Signatures Related to Breast Invasive Carcinoma Prognostic

Groza

Braicu

Jurj

et al. 2020

Cancers

View full text Add to dashboard Cite

Breast cancer is one of the most common oncological diseases in women, as its incidence is rapidly growing, rendering it unpredictable and causing more harm than ever before on an annual basis. Alterations of coding and noncoding genes are related to tumorigenesis and breast cancer progression. In this study, several key genes associated with epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) features were identified. EMT and CSCs are two key mechanisms responsible for self-renewal, differentiation, and self-protection, thus contributing to drug resistance. Therefore, understanding of the relationship between these processes may identify a therapeutic vulnerability that can be further exploited in clinical practice, and evaluate its correlation with overall survival rate. To determine expression levels of altered coding and noncoding genes, The Cancer Omics Atlas (TCOA) are used, and these data are overlapped with a list of CSCs and EMT-specific genes downloaded from NCBI. As a result, it is observed that CSCs are reciprocally related to EMT, thus identifying common signatures that allow for predicting the overall survival for breast cancer genes (BRCA). In fact, common CSCs and EMT signatures, represented by ALDH1A1, SFRP1, miR-139, miR-21, and miR-200c, are deemed useful as prognostic biomarkers for BRCA. Therefore, by mapping changes in gene expression across CSCs and EMT, suggesting a cross-talk between these two processes, we have been able to identify either the most common or specific genes or miRNA markers associated with overall survival rate. Thus, a better understanding of these mechanisms will lead to more effective treatment options.

show abstract

Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis

Cited by 22 publications

References 46 publications

Value of immunohistochemical determination of syndecan-1 in breast cancer

Value of immunohistochemical determination of syndecan-1 in breast cancer

Proteoglycans as Mediators of Cancer Tissue Mechanics

Cancer-Associated Stemness and Epithelial-to-Mesenchymal Transition Signatures Related to Breast Invasive Carcinoma Prognostic

Contact Info

Product

Resources

About